Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 172

Sort by

Sort Order Select

Journal Articles

Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML

Henri Sundquist, Mikael Tatun, Mikko Purhonen, Laura Toivanen, Johanna Rimpiläinen, Samuli Rounioja, Timo Siitonen, Marja Pyörälä, Pentti Mäntymaa, Sari Kytölä, Kimmo Porkka, Sanna Siitonen, Heikki Kuusanmäki, Mika Kontro, Oscar E. Brück

Blood (2024) 144 (Supplement 1): 4320.

https://doi.org/10.1182/blood-2024-206949

Published: 2024

Journal Articles

Deep Learning Models for Predicting Overall Survival of Acute Myeloid Leukemia Using Short-Term Longitudinal Blood Measurements and the Omop Common Data Model

Salma Rachidi, Alexey Ryzhenkov, Valtteri Nieminen, Tomi P Mäkelä, Oscar Brück, Kimmo Porkka, Eric Fey

Blood (2024) 144 (Supplement 1): 1476.

https://doi.org/10.1182/blood-2024-209871

Published: 2024

Journal Articles

Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes

Sofia Forstén, Livius Penter, Oscar E. Brück, Johannes Smolander, Karita Peltonen, Harri Lähdesmäki, Mika Kontro, Kimmo Porkka, Hussein A. Abbas, Catherine J. Wu, Jani Huuhtanen, Satu Mustjoki

Blood (2024) 144 (Supplement 1): 1529.

https://doi.org/10.1182/blood-2024-199471

Published: 2024

Journal Articles

Enabling Population-Scale Screening of Myeloid Neoplasms Using Blood Cell Count Dynamics

Oona Rinkinen, Laura Toivanen, Kimmo Porkka, Oscar E. Brück

Blood (2024) 144 (Supplement 1): 3612.

https://doi.org/10.1182/blood-2024-207261

Published: 2024

Journal Articles

Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML

Mikko Purhonen, Mikael Tatun, Kevin Hung, Oda Tafjord, Shady Adnan-Awad, Perttu Koskenvesa, Sanna Siitonen, Kimmo Porkka, Satu Mustjoki, Signe Danielsson, Henrik Hjorth-Hansen, Ulla Olsson-Strömberg, Takashi Kumagai, Shinya Kimura, David M Ross, Oscar E. Brück

Blood (2024) 144 (Supplement 1): 1780.

https://doi.org/10.1182/blood-2024-207253

Published: 2024

Journal Articles

Genomic Subtypes of AML Define Sensitivity to NK Cell Cytotoxicity

Hanna Duàn, Emmi Jokinen, Hanna Lähteenmäki, Jay Klievink, Jonas Bouhlal, Essi Laajala, Jason Theodoropoulos, Heikki Kuusanmäki, Tanja Ruokoranta, Pauliina Rumm, Dean Anthony Lee, Esa Pitkänen, Tomi P Mäkelä, Kimmo Porkka, Oscar E. Brück, Olli Dufva, Satu Mustjoki

Blood (2024) 144 (Supplement 1): 329.

https://doi.org/10.1182/blood-2024-199448

Published: 2024

Journal Articles

A First in Human Study of VOB560 in Combination with MIK665 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, or Multiple Myeloma

Blood (2024) 144 (Supplement 1): 5997.

https://doi.org/10.1182/blood-2024-199074

Published: 2024

Journal Articles

Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia

Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh B. Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman

Blood (2024) 144 (Supplement 1): 1560.

https://doi.org/10.1182/blood-2024-207199

Published: 2024

Journal Articles

Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial

Blood blood.2024024968.

https://doi.org/10.1182/blood.2024024968

Published: 2024

Includes: Supplemental data

Journal Articles

Targeting Mitochondrial Apoptotic Priming State to Personalize Therapy for Relapsed Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 48.

https://doi.org/10.1182/blood-2023-189156

Published: 2023

Journal Articles

Primary Acute Myeloid Leukemia Cells Trigger Distinct Activation Patterns in Expanded NK Cells

Hanna Duàn, Olli Dufva, Emmi Jokinen, Hanna Lähteenmäki, Jay Klievink, Jonas Bouhlal, Jason Theodoropoulos, Heikki Kuusanmäki, Tanja Ruokoranta, Pauliina Rumm, Dean Anthony Lee, Esa Pitkänen, Tomi P Mäkelä, Kimmo Porkka, Oscar Brück, Satu Mustjoki

Blood (2023) 142 (Supplement 1): 66.

https://doi.org/10.1182/blood-2023-174037

Published: 2023

Journal Articles

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Blood (2023) 142 (Supplement 1): 323.

https://doi.org/10.1182/blood-2023-184703

Published: 2023

Journal Articles

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2023-181709

Published: 2023

Journal Articles

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Blood (2023) 141 (21): 2657–2661.

https://doi.org/10.1182/blood.2022019160

Published: 2023

Includes: Supplemental data

Journal Articles

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Blood (2023) 141 (13): 1610–1625.

https://doi.org/10.1182/blood.2021011094

Published: 2023

Includes: Supplemental data

Journal Articles

Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia

Joseph Saad, Samuli Eldfors, Vilma Ikonen, Bjørn Tore Gjertsen, Mika Kontro, Kimmo Porkka, Caroline A. Heckman

Blood (2022) 140 (Supplement 1): 1033–1035.

https://doi.org/10.1182/blood-2022-163242

Published: 2022

Journal Articles

Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

Blood (2022) 140 (Supplement 1): 1030–1032.

https://doi.org/10.1182/blood-2022-159069

Published: 2022

Journal Articles

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Blood (2022) 140 (Supplement 1): 9125–9127.

https://doi.org/10.1182/blood-2022-157753

Published: 2022

Journal Articles

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 101–103.

https://doi.org/10.1182/blood-2022-158694

Published: 2022

Journal Articles

Integrated High-Throughput Drug Profiling and CRISPR Screening Identify Novel Pathway Vulnerabilities of Leukemic Stem Cells in Chronic Myeloid Leukemia

Shady Adnan Awad, Olli Dufva, Jay Klievink, Ella Karjalainen, Aleksandr Ianevski, Paavo Pietarinen, Daehong Kim, Swapnil Potdar, Maija Wolf, Kourosh Lotfi, Tero Aittokallio, Krister Wennerberg, Kimmo Porkka, Satu Mustjoki

Blood (2022) 140 (Supplement 1): 799–800.

https://doi.org/10.1182/blood-2022-165247

Published: 2022

NARROW

Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML

Deep Learning Models for Predicting Overall Survival of Acute Myeloid Leukemia Using Short-Term Longitudinal Blood Measurements and the Omop Common Data Model

Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes

Enabling Population-Scale Screening of Myeloid Neoplasms Using Blood Cell Count Dynamics

Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML

Genomic Subtypes of AML Define Sensitivity to NK Cell Cytotoxicity

A First in Human Study of VOB560 in Combination with MIK665 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, or Multiple Myeloma

Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia

Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial

Targeting Mitochondrial Apoptotic Priming State to Personalize Therapy for Relapsed Acute Myeloid Leukemia

Primary Acute Myeloid Leukemia Cells Trigger Distinct Activation Patterns in Expanded NK Cells

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia

Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

Integrated High-Throughput Drug Profiling and CRISPR Screening Identify Novel Pathway Vulnerabilities of Leukemic Stem Cells in Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only